Prof Kausik Ray

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917. PMID: 30865796 

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17. PMID: 28306389

Mendelian Randomization Study of ACLY and Cardiovascular Disease. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. N Engl J Med. 2019 Mar 14;380(11):1033-1042. doi: 10.1056/NEJMoa1806747. PMID: 30865797

Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mozenson, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D. for the SAVOR-TIMI 53 Steering Committee and Investigators . Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013 Oct 3;369(14):1317-26

Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko A, Kosiborod MN, McGuire DK, Harrington RA, on behalf of the THEMIS Steering Committee and Investigators.  Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet.  2019 Aug (30); pii: S0140-6736(19)31887-2. PMID: 31484629 doi: 10.1016/S0140-6736(19)31887-2

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators. Effect of Lorcaserin on Prevention and Remission of Type 2 Diabetes in CAMELLIA-TIMI 61, a randomized trial in overweight and obese patients. Lancet. 2018 Oct; pii: S0140-6736(18): 32328-6. doi: 10.1016/S0140-6736(18)32328-6. PMID: 30293771

Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of triglyceride-lowering LPL variants and LDL-C lowering LDLR variants with risk of coronary heart disease. JAMA. 2019 Jan(29); 321(4):364-373.  doi: 10.1001/jama.2018.20045. PMID: 30694319 

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MS. JAMA. 2019 Sep 2. doi: 10.1001/ jama.2019.14120. [Epub ahead of print] PMID:31475726

Ray KK, Stoekenbroek RM, Kallend D, NishikidoT, Leiter LA, Landmesser U, Wright RS, Wijngaard PLJ, Kastelein JJ.  Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.  JAMA Cardio.  2019 Sep (25). PMID: 31553410 doi: 10.1001/jamacardio.2019.3502

Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017 Aug 28; 318(10), 947-956 doi: 10.1001/jama.2017.11467. PMID: 28846118

Preiss, D., Seshasai, S. R. K., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., Ray, KK (2011, June 22). Risk of Incident Diabetes With Intensive-Dose Compare With Moderate-Dose Statin Therapy A Meta-analysis. JAMA, 2011, 305(24), 2556 2564

Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mozenson, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D. for the SAVOR-TIMI 53 Steering Committee and Investigators . Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013 Oct 3;369(14):1317-26.

Swerdlow D,….. Ray KK……Sattar N. HMG coenzyme A reductase inhibition, Type 2 diabetes and bodyweight: evidence from genetic analyses and randomised trials Lancet 2014 Sep 24^th, pii: S0140-6736(14)61183-1. doi: 10.1016/S0140-6736(14)61183-1

Ray KK, Vallejo-Vaz AJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26047976">The evolving role of CETP inhibition: beyond HDL cholesterol.</a> Lancet. 2015 Aug 1;386(9992):412-4. doi: 10.1016/S0140-6736(15)60608-0. Epub 2015 Jun 2. PMID: 26047976.

Vallejo-Vaz AJ, Ray KK. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25953923">Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?</a> Circ Res. 2015 May 8;116(10):1646-8. doi: 10.1161/CIRCRESAHA.115.305938. PMID: 25953923.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, .März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; for the European Atherosclerosis Society Consensus Panel. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25694464">Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.</a> Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. Review. PMID: 25694464.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. <a href="http://www.ncbi.nlm.nih.gov/pubmed/25802390">The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.</a> Eur Heart J.

Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, Nozue T, Sugiyama S, Tsimikas S, Yoshida H, Ray KK. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26074315">Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.</a> Atherosclerosis. 2015 Aug;241(2):409-18. doi: 10.1016/j.atherosclerosis.2015.06.001. Epub 2015 Jun 4. PMID: 26074315.